Pruritus
Recent clinical, regulatory, research and industry developments relating to this disease.
Marketing authorisation: Kayfanda (EMA)
Marketing authorisation: Kapruvia (EMA)
European S2k Guideline on Chronic Pruritus.
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q2 2027.
- 2 industry developments reported.
- Q2 2027A Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Moderate to Severe Pruritus in Peritoneal Dialysis Patients
- Q2 2027Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
- Q4 2027A Phase 2 Randomized Study of TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus
- Q3 2029KOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe Pruritus
Clinical MilestonesViewHide
- 2026-09-14A Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Moderate to Severe Pruritus in Peritoneal Dialysis PatientsResults expected Q2 2027
- 2026-09-01KOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe PruritusResults expected Q3 2029
- 2026-07-06Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)Results expected Q2 2027
- 2026-06-30A Phase 2 Randomized Study of TriCalm Hydrogel® in the Treatment of Immunotherapy-Related PruritusResults expected Q4 2027
- 2026-06-30Efficacy of Pregabalin for Diabetic Pruritus - A Randomized Controlled Study.Primary completion
Industry & MarketViewHide
- 2026-10-28Saroglitazar favors US patients for PBC response, pruritus reliefIndustry · Healio Gastroenterology
- 2026-10-15Pruritus declined within 2 weeks with volixibat in PSCIndustry · Healio Gastroenterology
- 2026-10-28IndustrySaroglitazar favors US patients for PBC response, pruritus reliefIndustry · Healio Gastroenterology
- 2026-10-15IndustryPruritus declined within 2 weeks with volixibat in PSCIndustry · Healio Gastroenterology
- 2026-09-14ClinicalA Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Moderate to Severe Pruritus in Peritoneal Dialysis PatientsResults expected Q2 2027
- 2026-09-01ClinicalKOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe PruritusResults expected Q3 2029
- 2026-07-06ClinicalMaster Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)Results expected Q2 2027
- 2026-06-30ClinicalA Phase 2 Randomized Study of TriCalm Hydrogel® in the Treatment of Immunotherapy-Related PruritusResults expected Q4 2027
- 2026-06-30ClinicalEfficacy of Pregabalin for Diabetic Pruritus - A Randomized Controlled Study.Primary completion
- 2026-05-01ClinicalA Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe PruritusResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Original application approval — Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALG… (2024)
Original application approval — Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with ch… (2022)
Original application approval — Livmarli is indicated for the treatment of: Cholestatic pruritus in patients with Alagil… (2022)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Cytokines1
- Dermatitis, Atopic1
- Eczema1
- Immune Checkpoint Inhibitors1
Leading journals6
- Acta dermato-venereologica1
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- JAMA dermatology1
- Journal of the European Academy of Dermatology and Venereology : JEADV1
- The Journal of investigative dermatology1
- The New England journal of medicine1
Leading researchers8
- Gieler U2
- Wollenberg A2
- Albornoz C1
- Armstrong AW1
- Bang A1
- Barbarot S1
- Berdyshev E1
- Blauvelt A1
Affiliations (unnormalised)6
- Aarhus University Hospital1
- Bern University Hospital1
- Centre Hospitalier Universitaire Vaudois1
- Christiane-Kühne Center for Allergy Research and Education (CK-Care)1
- Department of Pathology and Laboratory Medicine1
- Erasmus MC University Medical Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Pruritus is an intense itching sensation that creates an urge to rub or scratch the skin for relief. It is a common symptom in medicine and may occur as an isolated complaint or as part of another disease process. Chronic pruritus can arise from dermatologic or non-dermatologic conditions and may be multifactorial.
Pruritus may result from dermatological disease or from systemic, neurological, or psychiatric disease. It can also occur as a side effect of medications. In some cases, no single cause is identified and the itch is multifactorial.
The supplied grounding does not describe a specific biological mechanism for pruritus beyond the symptom of itch itself. It indicates that chronic pruritus can originate from skin disease, non-diseased skin, systemic illness, neurological disease, psychiatric disease, or medication effects. A precise diagnostic work-up is needed because the underlying mechanism depends on the cause.
Risk is increased by the presence of underlying skin disease, systemic disease, neurological disease, psychiatric disease, or exposure to medications that can cause itch. Chronic pruritus is reported more frequently in certain patient populations, including haemodialysis patients and patients with skin diseases such as urticaria and atopic dermatitis. The grounding also notes that chronic pruritus is common in the general population over a lifetime.
Management of chronic pruritus includes treatment of the underlying disease. It also includes topical treatment modalities and symptomatic therapy, but the supplied grounding does not specify drug classes beyond this general approach. A precise diagnostic work-up is part of standard management.
AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.